Including mRECIST in the Metroticket 2.0 criteria improves prediction of hepatocellular carcinoma-related death after liver transplant

Title
Including mRECIST in the Metroticket 2.0 criteria improves prediction of hepatocellular carcinoma-related death after liver transplant
Authors
Keywords
Hepatocellular carcinoma, Liver transplant, Neoadjuvant therapy, Survival, mRECIST
Journal
JOURNAL OF HEPATOLOGY
Volume -, Issue -, Pages -
Publisher
Elsevier BV
Online
2020-03-20
DOI
10.1016/j.jhep.2020.03.018

Ask authors/readers for more resources

Reprint

Contact the author

Find Funding. Review Successful Grants.

Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.

Explore

Create your own webinar

Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.

Create Now